Pre-clinical research has indicated that BPC-157 may have cytoprotective, neuroprotective, and anti-inflammatory effects, and may also accelerate tissue and organ healing. This substance is sometimes used in
functional medicine despite not being approved by any drug regulatory agency. The compound promotes
angiogenesis and as a result has some concerns over cancer promotion. As of 2022, the peptide has been banned by the
World Anti-Doping Agency under the S0 category of non-exempt substances. BPC-157 has been widely used both by athletes and among the general public, mainly for recovery from injury or stimulating healing in chronic conditions, but there is as yet only very limited human trial data on efficacy and only a few preliminary safety studies, so use of BPC-157 is discouraged by health authorities and it has been controlled as a prescription medicine in several jurisdictions such as New Zealand and Australia, despite not actually being available for prescription.
Detection BPC-157 is detected in urine using a weak cation exchange
solid phase extraction and was found to be stable in urine for 4 days. == See also ==